Moderna Stock Surges 130% on Cancer Vaccine Trial Success; Jitai Technology Named Chinese Comparable
On August 19, 2026, Moderna's personalized mRNA cancer vaccine recorded the world's first Phase 3 clinical trial success. The announcement lifted Moderna's share price by more than 130%, adding nearly $30 billion to its market value. In China, Jitai Technology has been identified as the domestic comparable company, operating the NanoForge platform with over 10 million ionizable lipid structures that enable targeted delivery to eight organs. Its lead candidate MTS-107 targets HPV16/18-linked malignancies. Jitai co-founder Chen Hongmin, an academician, is a disciple of Bob Langer, a Moderna founder and drug-delivery authority.
On August 19, 2026, Moderna's personalized mRNA cancer vaccine achieved the world's first successful Phase 3 clinical trial. Following the announcement, Moderna's share price rose by more than 130%, adding nearly $30 billion to its market capitalization.
mRNA tumor vaccines target tumor-associated antigens and can be used in combination with existing therapies to enhance the immune system's memory response, thereby reducing the risk of tumor recurrence and metastasis. LNP is the core technology for mRNA delivery, comprising four components: ionizable lipids, phospholipids, cholesterol, and PEG lipids. However, minor variations in formulation can lead to significant differences in delivery efficiency. Moderna previously paid Arbutus $2.25 billion to resolve LNP patent disputes.
Jitai Technology has been described as the world's first AI-driven nanodelivery company. Its proprietary NanoForge platform has built a library of more than 10 million ionizable lipid structures for LNP, enabling precision targeted delivery to eight organs: liver, lung, immune system, heart, muscle, tumor, central nervous system, and gastrointestinal tract. The platform has compressed the development time for preclinical targeted LNP delivery systems from one to two years to within three months.
Jitai Technology's pipeline candidate MTS-107 is an mRNA-based LNP delivery therapeutic vaccine targeting malignancies induced by HPV16 and HPV18, such as cervical cancer and head and neck cancer. The vaccine encodes the E6 and E7 antigens of HPV16/18, which are designed to be unable to degrade the p53 and Rb proteins, thereby eliminating carcinogenic risk, and combines a proprietary co-stimulatory adjuvant to enhance CD8+ T cell responses.
Jitai Technology co-founder, academician Chen Hongmin, is a disciple of Professor Bob Langer. Langer is one of Moderna's founders and a leading authority in drug delivery. Jitai Technology carries on Langer's academic legacy in drug delivery and integrates AI technology to drive its delivery platform.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Biotechnology, with intensity 85/100 and 90% confidence over a long term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.